Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Jones

Interventional Cardiology Columbia, SC Medical Doctor

NPI 1770582454 CMS profile 79999

8 Richland Medical Park Dr, Suite 300, Columbia, SC 29203

Open in the dashboard

General payments

$1,831

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Jones of Columbia, SC is reported in the CMS Open Payments database as having received $1,831 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 19th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77 3
2024 General $43 2
2023 General $887 46
2022 General $598 35
2021 General $51 3
2019 General $174 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Jones
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Benjamin Jones were reported at $77. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Benjamin Jones Interventional Cardiology median Middle half National median
2019 $174 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $51 $677 $233–$1,827 $132
2022 $598 $978 $333–$2,724 $149
2023 $887 $1,136 $382–$2,986 $160
2024 $43 $1,181 $395–$3,326 $164
2025 $77 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $700 43 payments
  2. Pfizer Inc. $322 19 payments
  3. Amgen Inc. $218 14 payments
  4. Alnylam Pharmaceuticals Inc. $160 8 payments
  5. E.R. Squibb & Sons, L.L.C. $119 7 payments
  6. Abbott Laboratories $85 2 payments
  7. Atricure, Inc. $58 2 payments
  8. Philips Electronics North America Corporation $40 2 payments
  9. Boston Scientific Corporation $31 1 payment
  10. Lexicon Pharmaceuticals, Inc. $24 1 payment
  11. Other $75 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,831 103 payments
Products named General payments · program years 2019–2025
  1. LEQVIO Cardiology/Vascular Diseases $428 22 payments
  2. ELIQUIS Cardiovascular;Metabolic Disease $229 14 payments
  3. Repatha $218 14 payments
  4. PAXLOVID $211 13 payments
  5. ENTRESTO Cardiovascular $192 15 payments
  6. ONPATTRO $160 8 payments
  7. ENTRESTO Cardiology/Vascular Diseases $150 9 payments
  8. LEQVIO Cardiovascular $110 8 payments
  9. ELIQUIS Cardiovascular $105 6 payments
  10. VYNDAQEL $73 4 payments
  11. Other $376 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

458

Median for Interventional Cardiology: 2,236

Drug cost

$112,277

Median for Interventional Cardiology: $380,412

Branded share of claims

33.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 92 $86,042
Xarelto Rivaroxaban Brand 15 $13,535
Jardiance Empagliflozin Brand 11 $5,990
Metoprolol Succinate Generic 48 $1,703
Flecainide Acetate Generic 19 $1,164
Atorvastatin Calcium Generic 34 $790
Rosuvastatin Calcium Generic 23 $636
Amlodipine Besylate Generic 52 $494
Losartan Potassium Generic 29 $385
Spironolactone Generic 20 $377

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $32
$32 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record